- Home
- ARHS vs NEO Comparison
ARHS vs NEO Comparison
Compare ARHS & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARHS
- NEO
- Stock Information
- Founded
- ARHS 1986
- NEO 2001
- Country
- ARHS United States
- NEO United States
- Employees
- ARHS N/A
- NEO N/A
- Industry
- ARHS Other Specialty Stores
- NEO Precision Instruments
- Sector
- ARHS Consumer Discretionary
- NEO Health Care
- Exchange
- ARHS Nasdaq
- NEO Nasdaq
- Market Cap
- ARHS 1.1B
- NEO 965.2M
- IPO Year
- ARHS 2021
- NEO 1999
- Fundamental
- Price
- ARHS $8.98
- NEO $7.28
- Analyst Decision
- ARHS Buy
- NEO Buy
- Analyst Count
- ARHS 13
- NEO 9
- Target Price
- ARHS $11.08
- NEO $13.31
- AVG Volume (30 Days)
- ARHS 2.0M
- NEO 1.7M
- Earning Date
- ARHS 05-08-2025
- NEO 04-29-2025
- Dividend Yield
- ARHS N/A
- NEO N/A
- EPS Growth
- ARHS N/A
- NEO N/A
- EPS
- ARHS 0.41
- NEO N/A
- Revenue
- ARHS $1,287,317,000.00
- NEO $672,361,000.00
- Revenue This Year
- ARHS $7.07
- NEO $13.95
- Revenue Next Year
- ARHS $7.71
- NEO $11.16
- P/E Ratio
- ARHS $21.91
- NEO N/A
- Revenue Growth
- ARHS 0.71
- NEO 10.10
- 52 Week Low
- ARHS $6.61
- NEO $6.08
- 52 Week High
- ARHS $19.81
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- ARHS 58.50
- NEO 38.30
- Support Level
- ARHS $7.94
- NEO $7.28
- Resistance Level
- ARHS $8.99
- NEO $7.63
- Average True Range (ATR)
- ARHS 0.41
- NEO 0.37
- MACD
- ARHS 0.07
- NEO -0.00
- Stochastic Oscillator
- ARHS 88.89
- NEO 12.42
About ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.